Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-04-02

FDA Approved: OLOPATADINE HCL — Supplemental Application (Sola Pharmaceuticals)

View source ↗

Summary

FDA supplemental application submission for olopatadine hydrochloride by Sola Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OLOPATADINE HCL (OLOPATADINE HCL)

Snippet

SUPPL AP for OLOPATADINE HCL (OLOPATADINE HCL)